Industry News
Research, Science & Manufacturer Updates
Celltrion’s Avtozma (tocilizumab-anoh), a biosimilar to Actemra (tocilizumab), in both intravenous and subcutaneous formulations, has been approved by the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has approved Vertex Pharmaceutical’s Journavx (suzetrigine), a new type of prescription pain medication for adults to treat moderate to severe acute pain.
Results of a recent study show patients with multiple myeloma undergoing teclistamab therapy may benefit from primary intravenous immune globulin supplementation, which appears to reduce the risk of high-grade infection.
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
A study published in Frontiers in Immunology has found the administration of intravenous immune globulin (IVIG) is associated with a reduction in sepsis mortality and favorable outcomes in laboratory parameters and the functional status, contributing to the ongoing debate on the efficacy of IVIG for sepsis.
A study led by researchers at Stanford Medicine has shown that variation in vaccine durability can, in part, be attributed to a type of blood cell called megakaryocytes, typically implicated in blood clotting.